IOL Chemicals gets Korean approval for Ibuprofen, Fenofibrate

Published On 2021-10-15 07:17 GMT   |   Update On 2023-10-11 12:03 GMT

New Delhi: Drug firm IOL Chemicals & Pharmaceuticals on Thursday said that it has received nod from the Korean Ministry of Food and Drug Safety for its active pharmaceutical ingredient (API) products -- Ibuprofen and Fenofibrate.

The approval by the Korean Ministry of Food and Drug Safety re-establishes the company's efforts to keep the highest quality standards and to increase presence in the regulated markets, IOL Chemicals & Pharmaceuticals said in a regulatory filing.

Also Read: Lupin Launches Generic Equivalent Of Northera Capsules In US

This will strengthen the company's presence in the South Korean market, it added.

Ibuprofen is used to treat a range of aches and pains, including back pain, period pain and toothache. Fenofibrate is used to treat the symptoms of high cholesterol and triglycerides in the blood.

Also Read: Lupin Unveils Generic Duexis Tablets In US

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News